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http:WHAT THIS PAPER ADDS
Flush infrarenal aortic occlusion (FIAO) is an uncommon ﬁnding in patients presenting with arterial insufﬁciency
of the lower limbs. Surgical repair has been considered the standard therapy for FIAO based on its long-term
durability and universal applicability though it is associated with substantial morbidity rates. We have investi-
gated transbrachial and femoral artery approach endovascular therapy with catheter-directed thrombolysis and
adjunctive therapy for ﬂush infrarenal aortic occlusion, which offers a safe and effective alternative to surgical
reconstruction in selected patients.Objective: The purpose of this study is to report the efﬁcacy of transbrachial and femoral artery approach
endovascular therapy with catheter-directed thrombolysis (CDT) and adjunctive therapy for ﬂush infrarenal aortic
occlusion (FIAO).
Materials and methods: From March 2012 to December 2013, 11 consecutive patients (9 males; mean age 68
years; range 54e80 years) were submitted to endovascular therapy for FIAO. All patients were treated with CDT
initially and then adjunctive endovascular treatments were performed to correct the underlying lesions.
Results: Complete reconstruction of occluded aortoiliac arteries was successfully achieved in 81.8% (9/11) of
patients. Left brachial and bilateral femoral arterial accesses were obtained in nine patients, and brachial and
unilateral femoral in two patients. The residual lesions after CDT were corrected in nine patients and concomitant
endovascular recanalization of superﬁcial femoral artery was performed in two patients. Self-expandable stents
were implanted in the all aortoiliac lesions with pre- and post-dilation. No renal or distal runoff embolization was
seen during intraoperative angiography. Seven (7/9) patients with rest pain or tissue loss showed signiﬁcant
improvements in symptoms and two (2/9) patients with intermittent claudication gained an improved walking
distance. The ABI rose signiﬁcantly between pre- and post-procedure (0.84  0.18 vs. 0.44  0.13 on the right
leg, p < .01; 0.89  0.23 vs. 0.48  0.16 on the left, p < .01).
Conclusions: Transbrachial and femoral artery approach endovascular therapy for FIAO offers an alternative to
surgical reconstruction with immediate outcomes.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Flush infrarenal aortic occlusion (FIAO) is an uncommon
ﬁnding in patients presenting with arterial insufﬁciency of
the lower limbs and it is seen in 3e5% of patients pre-
senting with aortoiliac occlusive lesions.1e3
Surgical bypass or endarterectomy have been considered
the standard therapy for FIAO based on its long-term
durability and universal applicability.4e6 However, surgical
revascularization is associated with substantial systemic orresponding authors. J. Bao, Z. Jing, Department of Vascular Surgery,
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//dx.doi.org/10.1016/j.ejvs.2014.04.001major morbidity (e.g. renal embolization), particularly in
elderly high-risk patients.7e9
Endovascular therapy has been developed as a minimally
invasive alternative for infrarenal aortoiliac occlusive dis-
ease with favorable long-term results.8,10 FIAO recanaliza-
tion by endovascular techniques such as chimney grafts
preserving renal ﬂow,11 Y-guide wire conﬁguration,12 and
directing stenting has been reported previously.13 However,
there are severe complications of releasing embolic parti-
cles that may occlude the renal arteries during directed
stenting.11
FIAO is often caused by an initial stenosis near the aortic
bifurcation, which may lead to retrograde thrombosis of the
abdominal aorta.9,11,14 Many patients may have recent
deterioration of lower extremity ischemia and older orga-
nized thrombus is likely coexistent with relatively new fresh
thrombus.15 Catheter-directed thrombolysis (CDT) is useful
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subsequent treatment decisions.16 In previous reports, CDT
has also been effective in removing partial chronic
thrombus with favorable results.17,18
The purpose of this study was to report the outcomes of
an endovascular approach to FIAO with CDT and adjunctive
treatments in 11 patients during last 21 months.METHODS
FromMarch 2012 toDecember 2013, 11 consecutive patients
(9males; mean 68 years; range 54e80 years) were submitted
to endovascular therapy for FIAO. Takayasu disease, ﬁbro-
muscular dysplasia, aortic coarctation, hypoplastic aorta
syndrome, and acute FIAO (less than 14 days) were excluded
from the study. None of the patients had a history of previous
surgical or endovascular intervention in the aortic, iliac, or
femoral arteries. Cessation of tobacco use, walking exercises,
and conservative medication regimens including aspirin, cil-
ostazol, and statin were tried but no signiﬁcant clinical
improvement was noted with any of them.
Pre-procedural assessment was performed in all patients
with computed tomography angiography or magnetic
resonance angiography to evaluate lesion site, length, and
distal runoff vessels. Written informed consent was ob-
tained from each patient after detailed explanation of the
risks and beneﬁts of the procedure and the study was
approved by the local ethics committee.
Under local anesthesia, a retrograde puncture of the
common femoral artery was performed initially and heparin
(125 IU/kg) was administered through the sheaths to pre-
vent development of pericatheter thrombus. The occluded
aorta could not be crossed retrogradely in all patients and
then access was gained via the left brachial artery. A 6F,
90 cm-long sheath (Cook, Bloomington, IN, USA) and a
pigtail catheter (Cook) was advanced into the suprarenal
aorta to perform the initial arteriogram. Once the guide
wire (Terumo, Tokyo, Japan) and 4F, 135 cm-long catheter
(Cordis, Bridgewater, NJ, USA) crossed the proximal cap, the
90 cm-long sheath was placed inside the renal artery level
to obtain a more stable position and the occluded segment
artery was recanalized intraluminally. After antegrade
recanalization of the occlusion, the brachial guide wire was
removed from the short sheath present in femoral artery,
using the “crossing sheath technique”. Then a selected
multi-side-hole thrombolytic catheter (AngioDynamics,
Latham, NY, USA) determined by the length of the occlusion
was navigated over the guide wire from the femoral artery
into the occluded segment. The contralateral iliac artery
was also recanalized intraluminally and another thrombo-
lytic catheter was navigated over the guide wire from the
brachial artery into the occluded segment.
Urokinase, 250,000 IU diluted in 50 mL of 0.9% NaCl, was
infused at 600 IU/kg per hour through the thrombolytic
catheter by microinfusion. The thrombolysis was acceler-
ated by pulse-spray infusion ﬁve times per day (250,000 IU
of urokinase diluted in 250 mL of 0.9% NaCl, and 50 mL was
used each time). Concurrently, 12,500 IU of unfractionatedheparin, diluted in 50 mL of 0.9% NaCl, was infused at
10 IU/kg per hour through the side arm of the sheath to
prevent pericatheter thrombosis.
Laboratory monitoring including activated partial
thromboplastin time (APTT), plasma ﬁbrinogen (Fbg) and D-
dimer levels was performed every 4 hours. Hemoglobin,
hematocrit, platelet count, and hepatic and renal function
were checked daily. The thrombolytic procedure was
stopped when the Fbg level dropped to <1.0 g/L. The effect
of heparin was monitored using APTT to keep it 1.5 to 2
times the control value.
Adjunctive endovascular treatments, including percuta-
neous transluminal angioplasty (PTA) and stenting, were
performed to correct underlying lesions. Balloons (6e8 mm
in diameter/60e150 mm in length; Admiral Xtreme, Invatec,
Roncadelle, Italy) from the brachial and femoral arteries (or
bilateral femoral arteries) simultaneously were used in kiss-
ing fashion. An extended proximal self-expandable bare stent
or single bare stent for aorta (14 mm in diameter/40e60 mm
in length; Smart, Cordis) was ﬁrstly deployed if the underlying
lesions were close to the renal arteries. Then self-expandable
stents (8 mm in diameter/60e150 mm in length; Smart,
Cordis) were deployed in the distal aorta and the common
iliac arteries in a kissing fashion in most patients (Fig. 1).
Endovascular treatments were also performed to correct le-
sions of the superﬁcial femoral artery. Completion angiog-
raphywas performed to demonstrate of the ﬁnal result and to
screen for renal and distal runoff embolization.
Technical success was deﬁned as restored vessel patency
with a residual stenosis <30% and no evidence of emboli-
zation to the renal arteries or distal runoff. Immediate he-
modynamic success was determined by an increase in ABI
of >0.10 postoperatively. Clinical success was deﬁned as a
subjective perception of improved walking distance,
absence of rest pain, and healing of trophic changes.
Complications included major bleeding (intracranial
bleeding, bleeding that resulted in death, or bleeding that
required transfusion, surgery, or cessation of thrombolytic
therapy), minor bleeding (deﬁned as less severe bleeding
managed by local compression, increasing vascular sheath
size, or decreasing dose of thrombolysis, anticoagulation, or
antiplatelet drug), renal and distal runoff embolization, and
acute renal failure.
Patients were discharged on an oral regimen of aspirin
(100 mg/day), clopidogrel (75 mg/day) and statin (20 mg/
day). Clinical examination and duplex ultrasonography was
performed before discharge, at 1, 3, and 6 months after
discharge, and every 6 months thereafter. Hemodynamic
evaluation was done by measuring the ankle-brachial index
(ABI) and duplex ultrasonography in all patients. Restenosis
was deﬁned as a drop in the ABI by 0.15, loss of palpable
pulses, a peak systolic velocity ratio 2.5 by ultrasonogra-
phy scan or development of ischemic symptoms. Computed
tomography angiography was performed only in cases of
recurrent stenosis >50% as measured on ultrasound scan.
Secondary reintervention may be necessary to maintain the
patency rate in the patients with severe claudication and
critical limb ischemia.
Figure 1. Digital subtraction angiography demonstrated that the aortic occlusion started proximally at the level of the renal artery and
extended distally to both common iliac arteries (A). Flush infrarenal aortic occlusion was treated with catheter-directed thrombolysis and a
ﬂow channel was achieved after 6 hours of thrombolysis (B,C). Self-expandable stents (14  40 mm deployed close to the renal arteries,
8  120 mm deployed in the distal aorta and the iliac arteries in a kissing fashion) were placed into the aorta and iliac arteries, and
angiography showed complete recanalization of the aortoiliac artery (D).
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(SPSS Inc., Chicago, IL, USA). The difference in ABI and
Rutherford category between pre- and postoperation was
analyzed with the Wilcoxon test and p < .05 was considered
statistically signiﬁcant.RESULTS
All 11 consecutive patients underwent endovascular
reconstruction and the clinical characteristics of the pa-
tients are shown in Table 1.
Of the 11 patients, nine had a history of claudication.
Eight of the nine patients had worsening symptoms and onepatient had claudication without aggravating history. The
remaining two of the 11 patients were characterized by rest
pain or ischemic ulcers. Concomitant unilateral superﬁcial
femoral artery occlusions were shown in three patients,
with bilateral stenosis in one. According to Rutherford
category, the clinical indication for endovascular therapy
was severe claudication (class III, n ¼ 4), rest pain (class IV,
n ¼ 5), and ischemic ulcers (class V, n ¼ 2).
Complete reconstruction of occluded aortoiliac arteries
with reestablishment of unimpeded blood ﬂow to both legs
was successfully achieved in 81.8% (9/11) patients.
Left brachial and bilateral femoral arterial accesses were
obtained in nine patients, and one brachial and one
Table 1. Characteristics of patients and lesions.
No. Age
(y)
Sex Clinical symptoms SFA (TASC
classiﬁcation)
Arterial
access
Thrombolytic effect Stenting for
aortoiliac lesions
Therapy for
distal runoff
RC Follow up Complication
Pre- Post-
1 80 M IC 1 y þ RP 2 mo Patency (e) Beb-F Proximal dissolution Proximal þ kissing No IV I 6 mo No
2 60 M IC 2 y þ aggravating
4 mo
Patency (e) BeF RH e e III II e e
3 61 M IC 6 mo þ aggravating
3 mo
Patency (e) Beb-F Proximal dissolution Kissing No III I 9 mo No
4 78 M IC 1 y þ RP 1 mo Stenosis/
bilateral (A)
Beb-F Proximal dissolution Kissing No IV II 21 mo No
5 54 M IC 2 y Patency (e) Beb-F Ineffective e e III I e Converted to
bypass
6 67 M RP 1 mo Occlusion/
left (C)
Beb-F Proximal dissolution Kissing Stenting IV I 12 mo Stenosis of SFA
7 71 M IC 6 mo þ IU 1 mo Occlusion/
right (B)
Beb-F Total aortic dissolution Right iliac No V II 18 mo No
8 69 M IC 4 mo þ RP 1 mo Patency (e) Beb-F Proximal dissolution Kissing No IV II 9 mo No
9 74 F IU 2 mo Occlusion/
left (C)
Beb-F Proximal dissolution Kissing Stenting V II 8 mo Hematoma
10 58 M IC 2 y þ RP 1 mo Patency (e) Beb-F Proximal dissolution Kissing No IV I 16 mo No
11 79 F IC 18 mo þ aggravating
3 mo
Patency (e) BeF Proximal dissolution Proximal No III I 3 mo Cerebral
infarction
IC ¼ intermittent claudication; y ¼ years; RP ¼ rest pain; mo ¼ months; IU ¼ ischemic ulcers; SFA ¼ superﬁcial femoral artery; BeF ¼ brachial and femoral access; Beb-F ¼ brachial and
bifemoral access; RH ¼ retroperitoneal hemorrhage; RC ¼ Rutherford category.
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50 L. Yuan et al.unilateral femoral in the remaining two patients. The mean
thrombolysis time was 12.5 hours (range 3e28 hours) with
mean urokinase dosage at 650,000 IU (range 200,000e
1,250,000 IU). Thrombolysis was effective for nine patients,
in whom the proximal or total aortic thrombosis dissolved,
transforming the ﬂush renal occlusion to more distal
infrarenal occlusion. Proximal thrombus dissolution after
CDT was not achieved in one patient (patient 5), who had
shown intermittent claudication for 2 years without aggra-
vating history. The patient was converted to aorto-bifemoral
bypass.
Residual lesions were corrected in nine patients with PTA
and stents. The aortoiliac lesions were stented with self-
expandable stents using the “kissing” technique in six pa-
tients. Beside distal kissing stents, a proximal bare stent was
also deployed close to renal arteries in one patient (patient
1). Deployment of only one bare stent was achieved in the
aorta for one patient (patient 11), and a single stent for the
right iliac artery in one patient (patient 7). Superﬁcial
femoral arteries were also involved in four patients and
concomitant endovascular recanalization was performed in
two patients (patients 6 and 9). Concomitant renal stenting
was performed in one patient (patient 1) because of ste-
nosis of the renal artery. Self-expandable stents (1e3; mean
1.9) with pre- and post-dilation were implanted in all aor-
toiliac lesions.
No renal or distal runoff embolization was found during
intraoperative angiography. Retroperitoneal hemorrhage
occurred in one patient 3 hours after thrombolysis, with a
fall in blood pressure and reduced hemoglobin. The patient
recovered gradually by stopping CDT and rehydration, but
refused further endovascular surgery. One patient suffered
from hematoma at the brachial puncture site, but had no
need of further treatment.
After a mean 11.3 months follow-up (range 3e21
months), there were no deaths and no amputations. Minor
cerebral infarction occurred in one patient (patient 11) 1
month postoperatively, but the patient recovered without
residual symptoms. Two (2/9) patients with severe inter-
mittent claudication had improved walking distance and ﬁve
(5/9) patients with ischemic pain showed signiﬁcant
improvement in symptoms 1 month after the operation.
Ischemic ulcers in two (2/9) patients healed at 2 and 3
months postoperatively, and no reoccurrence of ischemic
ulcers was observed. As expected, the ABI had risen
signiﬁcantly between pre- and post-procedure (0.84  0.18
vs. 0.44  0.13 on the right leg, p < .01; 0.89  0.23 vs.
0.48  0.16 on the left, p < .01).
In-stent restenosis of the aortoiliac artery did not occur
on the basis of ultrasonography. One patient (patient 6) had
restenosis of the SFA based on ultrasonography; the patient
did not have lifestyle-limiting symptoms and refused
reintervention.DISCUSSION
FIAO is a serious condition, and thus far surgical recon-
struction is considered the standard therapy.1e3 However,aorto-bifemoral bypass is associated with signiﬁcant peri-
operative morbidity.4,19e21 Endovascular surgery has proven
to be an excellent alternative to open surgery for short and
complex aortoiliac disease, providing patency rates very
similar to those obtained with open surgery.13,17,18,22,23
Directed endovascular therapy for FIAO without CDT has
only been reported in few cases1,12,13,24 and outcomes after
endovascular treatment are less well-deﬁned. In this study,
FIAO was recanalized using transbrachial and femoral artery
approach endovascular therapy, proving it to be technically
feasible.
Fresh thrombus on an existing atherosclerotic stenosis is
often the reason for aggravating symptoms, and eight pa-
tients showed this. The treatment of relatively fresh
thrombus is important for FIAO. Ballooning or direct
stenting may extrude or cut aortic thrombus and carry a risk
of releasing embolic particles that may occlude renal or
distal arteries.11 CDT therapy has been accepted as a
minimally invasive method of accelerated thrombolysis by
increasing the surface area available for enzymatic action. In
this study, although there were always signiﬁcant residual
lesions that required adjunctive endovascular treatments,
CDT dissolved proximal or total aortic thrombus in nine
patients and transformed ﬂush renal to focal infrarenal
occlusion, which may decrease the risk of renal emboliza-
tion and make treatment of the occlusion near the renal
arteries safer.
In this study, besides one patient who suffered from
retroperitoneal hemorrhage, CDT was not effective for
proximal thrombus dissolution in only one patient, who
presented chronic intermittent claudication for 2 years
without aggravating history. The patient was converted to
aorto-bifemoral bypass and the initial endovascular strategy
did not preclude open surgical management. CDT was
effective in dissolving proximal thrombus in the other nine
patients with critical ischemia of less than 2 months or with
an aggravating ischemia period of up to 4 months. Theo-
retically, organized chronic arterial thrombus (>14 days)
may be relatively refractory to thrombolysis. However,
there were several reports in which (partial) dissolution of
chronic thrombus was achieved with CDT for peripheral
arteries.18,25e27 In this study, the CDT was effective in dis-
solving thrombus in patient 2, who had the longest aggra-
vating history of 4 months (IC 2 y and aggravating 4 m).
Based on this experience and other reports,26,27 CDT may
be effective in dissolving short-term thrombus (less than 6
months) and so it is important to select appropriate pa-
tients according to limb ischemic history.
Ensuring the guide wires cross the occluded lesions
intraluminally is critical to successful CDT and adjunctive
endovascular therapy. In this study, retrograde recanaliza-
tion of aortic lesions from the femoral artery was tried in all
patients, but when it failed, access was gained via the left
brachial artery. Moise28 used the left brachial artery as a
standard access point in all patients because of the ease of
ensuring the guide wires cross the occluded lesions to both
iliac arteries intraluminally. Subintimal angioplasty carried
an additional risk of perforation during extensive attempts
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minimized by crossing the occluded lesions from the
brachial artery when subintimal dissection was suspected
from the femoral artery.
Based on the relatively longer occlusion and the ﬁnding
of non-heavily calciﬁed lesions conﬁrmed by predilation in
this series, self-expanding stents were used in all aortoiliac
lesions for their superior ﬂexibility and ability to adapt to
vessel tortuosity. In other studies,17,30 self-expanding stents
were also used because they can trap atherothrombotic
material more effectively owing to their smaller struts and,
theoretically, reduce the likelihood of distal embolization.
Stent grafts had also been deployed to decrease the need
for repeat interventions and to avoid arterial rupture from
balloon inﬂation.28,31 However, a potential disadvantage of
stent grafts is the need for relatively large delivery sheaths
and coverage of patent lumbar and collateral arteries.
One of the most dreaded complications of endovascular
therapy for FIAO is renal embolization. Directly stenting the
ﬂush thrombosed infrarenal aortic segment carries a risk of
releasing embolic particles that may lead to embolization of
the renal arteries.11,13 In this series, direct stenting for FIAO
was avoided and the ﬂush infrarenal occlusion was trans-
formed to a more distal infrarenal lesion with CDT.
There are limitations to the study. It was a retrospective,
nonrandomized analysis with a small group of patients with
short follow-up. Thus, a further study is required to evaluate
the long-term results of transbrachial and femoral artery
approach endovascular therapy for more FIAO patients.
CONCLUSION
Transbrachial and femoral artery approach endovascular
therapy for FIAO offers an alternative to surgical recon-
struction with immediate outcomes. Extended follow-up
with longer-term results and larger numbers of patients is
required before this technique can be widely advocated.
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